Ocriplasmin for Vitreoretinal Diseases
Open Access
- 14 October 2012
- journal article
- review article
- Published by Wiley in Journal of Biomedicine and Biotechnology
- Vol. 2012, 1-6
Abstract
Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.Keywords
This publication has 49 references indexed in Scilit:
- Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a reviewClinical Ophthalmology, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- POSTERIOR VITREOUS DETACHMENT WITH MICROPLASMIN ALTERS THE RETINAL PENETRATION OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN RABBIT EYESRetina, 2011
- Ultrastructural Correlation of Spectral-Domain Optical Coherence Tomographic Findings in Vitreomacular Traction SyndromeAmerican Journal of Ophthalmology, 2008
- PLASMIN ENZYME-ASSISTED VITREORETINAL SURGERY IN CONGENITAL X-LINKED RETINOSCHISISRetina, 2007
- PLASMIN-ASSISTED VITRECTOMY FOR MANAGEMENT OF PROLIFERATIVE MEMBRANE IN PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2007
- AUTOLOGOUS PLASMIN FOR PHARMACOLOGIC VITREOLYSIS PREPARED 1 HOUR BEFORE SURGERYRetina, 2006
- Intravitreal Plasmin Injection Activates Endogenous Matrix Metalloproteinase-2 in Rabbit and Human VitreousAmerican Journal of Ophthalmology, 2006
- Plasmin activates pro‐matrix metalloproteinase‐2 with a membrane‐type 1 matrix metalloproteinase‐dependent mechanismJournal of Cellular Physiology, 2002
- Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holesOphthalmology, 1998